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Abstract
Background: The EGFR and HER2 genes are located on chromosomes 7 and 17, respectively. They are
therapeutic targets in some tumors. The TOP2A gene, which is located near HER2 on chromosome 17,
is the target of many chemotherapeutic agents, and co-amplification of HER2 and TOP2A has been
described in several tumor types. Herein, we investigated the gene status of EGFR, HER2, and TOP2A in
Chinese gastric carcinoma patients. We determined the rate of polysomy for chromosomes 7 and 17, and
we attempted to clarify the relationship between EGFR, HER2, and TOP2A gene copy number and
increased expression of their encoded proteins. Furthermore, we tried to address the relationship
between alterations in EGFR, HER2, and TOP2A and chromosome polysomy.
Methods: One hundred cases of formalin fixed and paraffin embedded tumor tissues from Chinese gastric
carcinoma patients were investigated by immunohistochemistry and fluorescence in situ hybridization
(FISH) methods.
Results: Forty-two percent of the cases showed EGFR overexpression; 16% showed EGFR FISH positive;
6% showed HER2 overexpression; and 11% showed HER2 gene amplification, including all six HER2
overexpression cases. TOP2A nuclear staining (nuclear index, NI) was determined in all 100 tumors: NI
values ranged from 0.5 – 90%. Three percent of the tumors showed TOP2A gene amplification, which
were all accompanied by HER2 gene amplification. Nineteen percent of the tumors showed chromosome
7 polysomy, and 16% showed chromosome 17 polysomy. Chromosome 7 polysomy correlated
significantly with EGFR FISH-positivity, but was not associated with EGFR overexpression. HER2
overexpression associated significantly with HER2 gene amplification. TOP2A gene amplification was
significantly associated with HER2 gene amplification. No relationship was found between alterations in
the EGFR, HER2, and TOP2A genes and clinicopathologic variables of gastric carcinoma.
Conclusion: The data from our study suggest that chromosome 7 polysomy may be responsible for
increased EGFR gene copy number in gastric carcinomas, and that HER2 gene amplification may be the
major reason for HER2 protein overexpression. A combined investigation of the gene status of EGFR,
HER2, and TOP2A should facilitate the identification of a target therapeutic regimen for gastric carcinoma
patients.
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Background
Gastric cancer is now the second most common cause of
cancer death worldwide. Gastric cancer treatment remains
a challenge for physicians. Recently, targeted therapy has
been applied to gastric carcinoma, which may open new
avenues for cancer treatment. Current targeted therapy
depends on the evaluation of the status of target
genes[1,2].
EGFR and HER2 are members of the epidermal growth
factor receptor (EGFR) superfamily with tyrosine kinase
activity. EGFR and HER2 are amplified and overexpressed
in many human epithelial malignancies, including
NSCLC, breast cancer, ovarian cancer, and other forms of
cancer; they have both been identified as potential thera-
peutic targets in several solid tumors, although few reports
have focused on gastric carcinoma [3-5]. EGFR and HER2
are located at chromosome bands 7p12 and 17q12-q21,
respectively; they encode 185 kDa and 170 kDa plasma
membrane glycoproteins, respectively. Previous studies
revealed that gene amplification was the main cause of
HER2 protein overexpression. However, the reason for
EGFR protein overexpression is more complex, it is not
known whether EGFR gene copy number correlates with
EGFR protein overexpression[3]. Several molecules have
been synthesized that inhibit EGFR and HER2 tyrosine
kinase domains. These tyrosine kinase inhibitors pro-
duced significant responses in advanced NSCLC and
breast cancer, and some have been used in the treatment
of gastric cancer. Recently, dual inhibition strategies,
which target both EGFR and HER2, have shown promis-
ing effects against some tumors. Therefore, investigating
the gene status of EGFR and HER2 is crucial to determin-
ing those patients who would benefit most from target
therapies [6-8].
The topoisomerase IIa gene (TOP2A), which is located on
chromosome 17q12-q21 near the HER2 oncogene,
encodes an enzyme involved in DNA replication. TOP2A
is the target enzyme for a specific class of anticancer drugs
called anthracyclines. Recent studies have shown that co-
amplification of HER2 and TOP2A is associated with sen-
sitivity to anthracycline therapy in several types of cancer.
Whether TOP2A gene amplification leads to TOP2A pro-
tein overexpression remains controversial [9,10]. A rela-
tionship between EGFR and TOP2A has not been
reported. Recently, polysomy of chromosome 7, where
EGFR resides, was reported to be associated significantly
with improved survival after gefitinib treatment in NSCLC
patients; based on this finding, chromosome 7 polysomy
was considered a predictor for EGFR target therapy[11].
Chromosome 17 aneusomy was common in invasive
breast cancer specimens, but correlated primarily with low
polysomy 17. Aneusomy for chromosome 17 was not a
significant factor for HER2 protein overexpression or for
the clinical assessment of HER2 gene status [12]. Previous
studies have not shown a relationship between aneusomy
for chromosome 17 and TOP2A gene amplification or
protein overexpression.
In the current study, EGFR, HER2, and TOP2A gene copy
numbers and corresponding levels of protein expression
in Chinese gastric carcinomas were determined by FISH
and immunohistochemistry(IHC), respectively. Further-
more, polysomy for chromosome 7, where EGFR resides,
and for chromosome 17, where HER2 and TOP2A reside,
were determined. These experiments allowed the analysis
of the relationship between EGFR, HER2, and TOP2A
gene copy number and corresponding protein overexpres-
sion. The correlation between EGFR, HER2, and TOP2A in
gastric carcinomas was determined. Finally, the relation-
ship between chromosome 7 polysomy and EGFR ampli-
fication/overexpression, and the relationship between
chromosome 17 polysomy and HER2/TOP2A amplifica-
tion/overexpression were also evaluated.
Methods
Tumor tissue collection and human subjects approval
The specimens were selected from archive paraffin embed-
ded blocks in Peking Union Medical College Hospital by
two pathologists, 793 Chinese patients with gastric aden-
ocarcinoma who underwent surgery at the Department of
Surgery, Peking Union Medical College Hospital were eli-
gible to be selected for the period of 2000–2005. Only
those patients whose clinical data (include diagnosis, age,
sex, address, disease history, etc) were intact and the
blocks were enough to be cut into 20 slides were selected,
and patients from different areas of China were included.
One hundred Chinese patients with gastric adenocarci-
noma were finally selected in this study. As the sample
size is small and specimens with small tumor size (not
enough to make 20 slides) were excluded, the significance
of this study may be limited. Because no previous data
from Chinese patients has been published before, we
present our data as a reference. If the sample size would
have been larger, the results would be more representa-
tive, which is a limitation of our study.
The patient group was composed of 82 males and 18
females, with an average age of 60 years. Cancer staging
was classified according to the TNM cancer staging system
of the American Joint Committee of Cancer[13]: stage IA,
12 cases; stage IB, 7 cases; stage II, 16 cases; stage IIIA, 31
cases; stage IIIB, 11 cases; and stage IV, 23 cases. The
World Health Organization Classification of Tumors was
used for histologic classification and grading[14]. The
institutional review board at the Peking Union Medical
College Hospital approved this study, and informed con-
sent was obtained from all patients.BMC Cancer 2008, 8:363 http://www.biomedcentral.com/1471-2407/8/363
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Immunohistochemistry
All gastric tumor specimens were fixed in 10% buffered
formalin and embedded in paraffin according to standard
procedures. Serial sections (4 μm thickness) placed on
positively charged slides (MENZEL-GLASSER, GERMAN)
were used for hematoxylin and eosin staining, immuno-
histochemistry, and FISH detection of EGFR, HER2, and
TOP2A.
Immunohistochemical detection of HER2, EGFR, and
TOP2A was determined in all 100 primary gastric cancer
tumors. Immunohistochemistry for EGFR and HER2 was
performed using the EGFR pharmDx kit (DakoCytoma-
tion, Denmark), and the HercepTest kit (DakoCytoma-
tion, Denmark), respectively, according to the
manufacturer's instructions. A monoclonal antibody
against TOP2A (Genetech, Shanghai, China) was used for
TOP2A immunohistochemical detection, and TOP2 anti-
gen retrieval was performed by autoclaving in 10 mmol/L
citrate buffer (pH 6.0) for 10 minutes at 121.8°C. Anti-
body binding was visualized by the EnVison detection kit
(DakoCytomation, Denmark).
Immunohistochemical staining for EGFR and HER2 was
evaluated following the criteria recommended by the
manufacturer: 0, no discernible staining or background
type staining; 1+, equivocal discontinuous membrane
staining; 2+, unequivocal membrane staining with mod-
erate intensity; and 3+, strong and complete plasma mem-
brane staining. More than 30% of the cells were required
to meet the criteria for HER2 analysis according to recent
published guidelines[15], and more than 10% of the cells
were required to meet the criteria for EGFR analysis.
Scores of 2+ and 3+ staining levels were considered to be
EGFR overexpression, Scores of 3+ staining levels were
considered to be HER2 overexpression. Evaluation of
TOP2A-positive cells was determined by assessing the pro-
portion of positive tumor cell nuclei within a neoplasm;
the percentage of positively stained nuclei was calculated
by examining 200 cancer cells and was expressed as the
nuclear index (NI).
FISH analysis
EGFR FISH analysis
EGFR FISH analysis was carried out using the LSI EGFR
SpectrumOrange/CEP 7 SpectrumGreen probe (Vysis,
Abbott Laboratories) according to the manufacturer's pro-
tocol. Sections were incubated at 56°C overnight, depar-
affinized by washing in CitriSolv (Fisher Scientific,
Pittsburgh, PA), and dehydrated in 100% ethanol. After
incubation in 2× saline sodium citrate buffer (2× SSC, pH
7.0) at 75°C for 15 – 25 minutes, sections were digested
with proteinase K (0.25 mg/mL in 2× SSC; pH 7.0) at
37°C for 15 – 25 minutes, rinsed in 2× SSC at room tem-
perature for 5 minutes, and dehydrated in a series of
increasing concentrations of ethanol (70%, 85%, and
100%). The EGFR/CEP 7 probe set was applied to the
selected area based on the presence of tumor foci on each
slide, and the hybridization area was covered with a glass
coverslip and sealed with nail polish. The slides were incu-
bated at 80°C for 8 – 10 minutes for co-denaturation of
the chromosomal and probe DNA and were then hybrid-
ized at 37°C for 20 – 24 hours. Post-hybridization washes
were performed in 1.5 M urea and 0.1× SSC (pH 7.0 – 7.5)
at 45°C for 30 minutes and in 2× SSC for 2 minutes at
room temperature. After the samples were dehydrated in
ethanol as above, 4',6'-diamidino-2-phenylindole (DAPI)
in phosphate-buffered saline and glycerol (Vysis) was
applied for chromatin counterstaining. FISH analyses
were performed independently by two authors who were
blinded to the clinical characteristics of the patients and to
all other molecular variables. For EGFR FISH analyses, 60
nuclei were scored for signals from both DNA probes
using an Olympus BX51TRF microscope (Olympus,
Japan) equipped with a triple-pass filter (DAPI/Green/
Orange; Vysis) at a final magnification of 1000×.
Chromosome 7 polysomy and monosomy were defined
as ≥ three signals and one signal, respectively, in more
than 20% of the tumor cells. EGFR gene status was classi-
fied into six categories according to the frequency of
tumor cells with specific copy numbers of the EGFR gene
and the chromosome 7 centromere as described else-
where [16-18]: disomy (≤ 2 copies in > 90% of cells), low
trisomy (≤ 2 copies in ≥ 40% of cells, 3 copies in 10 – 40%
of cells, and ≥ 4 copies in < 10% of cells), high trisomy (≤
2 copies in ≥ 40% of cells, 3 copies in ≥ 40% of cells, and
≥ 4 copies in < 10% of cells), low polysomy (≥ 4 copies in
10 – 40% of cells), high polysomy (≥ 4 copies in ≥ 40% of
cells), and gene amplification (presence of tight EGFR
gene clusters and a ratio of the EGFR gene to chromosome
7 of ≥ 2, or ≥ 15 copies of EGFR per cell in ≥ 10% of cells).
Based on the EGFR gene status, patients were further clas-
sified into two groups: 1) EGFR FISH-negative or low gene
copy (disomy, low trisomy, high trisomy, and low polys-
omy), and 2) EGFR FISH-positive or high gene copy (high
polysomy and gene amplification). For each FISH prepa-
ration, known positive and negative cells were used as
controls.
TOP2A and HER2 FISH analysis
Three-color FISH to assess the copy number of TOP2A and
HER2 was performed using a probe set consisting of Spec-
trumOrange-labeled TOP2A, SpectrumGreen-labeled
HER2, and SpectrumAqua-labeled centromere 17 (Vysis);
the CEP 17 probe was used as a chromosomal copy
number control. Absolute and relative numbers (relative
to chromosome 17 copy number) of the individual genes
were scored in at least 40 cancer nuclei per tumor. FISH
labeling was performed according to the Vysis protocolBMC Cancer 2008, 8:363 http://www.biomedcentral.com/1471-2407/8/363
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and as described previously. Briefly, hybridization buffer,
DNA probe, and purified water were combined, centri-
fuged, and heated to 73°C for 5 minutes in a water bath.
Slides were immersed in a denaturing bath (70% forma-
mide/2× SSC) for 5 minutes at 73°C, followed by dehy-
dration in increasing ethanol concentrations, and then
dried. The probe mix was applied to each slide, and slides
were placed in a 42°C incubator for 30 minutes. Slides
were subsequently washed in 0.4× SSC/0.3% NP-40 for 2
minutes, air-dried in darkness, counterstained with DAPI,
and a coverslip was applied. All levels for HER2 and
TOP2A are reported as a gene/CEP 17 ratio to normalize
to the total chromosome number within each cell. Ampli-
fication was defined as a gene/CEP 17 ratio of 2.2[15].
Disomy for chromosome 17 was defined as an average of
1.75 to 2.25 CEP17 signals per cell, whereas cases with <
1.75 (hypodisomy) or > 2.25 (polysomy) CEP 17 signals
per cell were defined as having aneusomy for chromo-
some 17[12,19]. For each FISH preparation, known posi-
tive and negative cells were used as controls.
Statistical analysis
Statistical analyses were performed using Pearson's Chi-
square test or Fisher's exact test to determine significant
clinicopathological differences between EGFR expression
in both positive and negative tumors, between EGFR
FISH-positive and FISH-negative tumors, between tumors
with and without TOP2A overexpression/amplification,
and between HER2 expression/amplification in positive
and negative tumors; to determine the association
between EGFR overexpression and EGFR gene status,
between HER2 overexpression and HER2 gene status, and
between TOP2A NI and TOP2A gene status; and to inves-
tigate the relationship between gene status and chromo-
somal polysomy. Odds ratio and 95% confidence
intervals (CIs) were calculated. Nineteen comparisons
were performed, after a Bonferroni adjustment was made
to adjust for multiple comparisons, and the difference at
P < 0.0026(0.05/19) was considered significant.
Results
Correlation with clinicopathologic variables
No significant relationship was found between clinico-
pathologic variables (sex, age, tumor differentiation,
stage, or TNM classification) and EGFR overexpression,
EGFR high polysomy/amplification, HER2 overexpres-
sion, HER2 amplification, TOP2A overexpression, TOP2A
amplification, chromosome 7 polysomy, or chromosome
17 polysomy.
EGFR status in gastric carcinoma
Eleven percent of the cases showed EGFR expression levels
corresponding to 3+, 31% showed EGFR levels of 2+, and
5% showed EGFR levels of +; the remaining 53% of cases
showed level 0 staining (n = 100 gastric tumor samples).
Three percent of the cases showed EGFR amplification,
13% showed high polysomy, 28% showed low polysomy,
24% showed low trisomy, 32% showed disomy, and none
of the cases showed high trisomy. EGFR overexpression
was not associated with EGFR FISH positivity (high poly-
somy and amplification) (p > 0.0026) (Table 1, Figure 1).
EGFR status and chromosome 7 polysomy
Nineteen percent of the cases showed chromosome 7
polysomy; 10 out of the 19 cases with chromosome 7
polysomy showed EGFR high polysomy, and the remain-
ing nine cases showed EGFR low polysomy. Nine of the
19 cases showed EGFR overexpression. Chromosome 7
polysomy showed a significant association with EGFR
FISH-positivity after Bonferroni correction (p < 0.0001).
Chromosome 7 polysomy showed no association with
EGFR overexpression (p > 0.0026) (Table 2).
HER2 status in gastric carcinoma
Six percent of the cases showed HER2 3+ levels, and 7%
showed HER2 2+ levels. Sixteen percent of the cases
showed HER2 1+ levels, and the remaining 71% of the
cases showed a 0 level of HER2 staining. Eleven percent of
the cases showed HER2 gene amplification; the HER2
amplification cases included all six of the HER2 3+ cases,
three of the HER2 2+ cases, and two of the HER2 0 cases
by immunohistochemistry. HER2 overexpression (3+)
showed a significant association with HER2 amplification
after Bonferroni correction (p < 0.0001) (Table 3, Figure
2).
HER2 status and chromosome 17 aneusomy
Sixteen percent of the cases showed chromosome 17 poly-
somy, 8 percent of the cases showed chromosome 17
hypodisomy, the other 76 percent of the cases showed dis-
omy. One of the 16 cases with chromosome 17 polysomy
showed HER2 amplification and HER2 IHC levels of 3+.
There was no association between chromosome 17 polys-
omy and HER2 amplification (p > 0.0026), and there was
no significant association between chromosome 17 poly-
somy and HER2 overexpression (p > 0.0026) (Table 4).
TOP2A status in gastric carcinoma
TOP2A protein expression was detected in all 100 tumors:
NI values ranged from 0.5 – 90%, and three cases showed
TOP2A amplification with NI values of 20%, 40%, and
50%, respectively (Figure 3, 4). No TOP2A deletions were
detected in any of the 100 tumor specimens. None of the
16 chromosome 17 polysomy cases showed TOP2A
amplification.
To determine whether the TOP2A expression evident in
gastric adenocarcinomas was a result of gene amplifica-
tion or chromosome 17 polysomy, we established three
cut-off points for TOP2A NI values at 5%, 10%, and 25%,BMC Cancer 2008, 8:363 http://www.biomedcentral.com/1471-2407/8/363
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and tried to identify the statistical difference in the pres-
cence of TOP2A amplification or chromosome 17 polys-
omy with a cut-off less than 5%(or10%,25%) vs 5%
(or10%,25%)or more. No correlation was found between
TOP2A amplification and TOP2A NI values (p > 0.0026)
(Table 5). No association was found between choromo-
some 17 polysomy and TOP2A NI values (p > 0.0026).
No significant association was found between chromo-
some 17 polysomy and TOP2A amplification (p >
0.0026) (Table 6) (Figure 2).
Correlation between EGFR status and HER2 status
Among the 13 tumors with HER2 overexpression, seven
(53.8%) showed EGFR overexpression. There was no sig-
nificant relationship between HER2 expression and EGFR
overexpression (p > 0.0026). Among the 11 tumors with
HER2 amplification, three showed EGFR high polysomy,
none showed EGFR gene amplification, and there was no
significant relationship between HER2 gene amplification
and EGFR high polysomy and/or EGFR gene amplifica-
tion (p > 0.0026) (Figure 3).
A: Case 10, immunohistochemistry showed EGFR positive(3+) in gastric adenocarcinoma, B: Immunohistochemistry showed  EGFR negative(0) control in gastric adenocarcinoma, C: Case 10, FISH result showed EGFR amplification (red signal in cluster)  in gastric adenocarcinoma Figure 1
A: Case 10, immunohistochemistry showed EGFR positive(3+) in gastric adenocarcinoma, B: Immunohisto-
chemistry showed EGFR negative(0) control in gastric adenocarcinoma, C: Case 10, FISH result showed EGFR 
amplification (red signal in cluster) in gastric adenocarcinoma.BMC Cancer 2008, 8:363 http://www.biomedcentral.com/1471-2407/8/363
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Correlation between EGFR status and TOP2A status
There was no association between TOP2A NI levels and
EGFR overexpression (p > 0.0026). Among the three
tumors with TOP2A gene amplification, one showed
EGFR high polysomy, none showed EGFR gene amplifica-
tion, and there was no association between TOP2A gene
amplification and EGFR high polysomy and/or EGFR
gene amplification (p > 0.0026) (Figure 3).
Correlation between HER2 status and TOP2A status
There was no significant relationship between TOP2A NI
levels and HER2 overexpression (p > 0.0026). Among the
three tumors with TOP2A gene amplification, two
showed HER2 gene amplification, demonstrating a signif-
icant correlation between TOP2A amplification and HER2
amplification (p < 0.0001) (Figure 2, 3), still significant
after Bonferroni correction.
Discussion
In this study, we demonstrated that EGFR, HER2, and
TOP2A were overexpressed and amplified in gastric carci-
nomas from Chinese patients; similar results were
observed in Western countries and in other Asian coun-
tries [19-22]. Therefore, it is reasonable to focus on EGFR,
HER2, and TOP2A overexpression and/or gene amplifica-
tion when developing therapeutic strategies to target gas-
tric carcinomas. Furthermore, it will be important to
evaluate the status of the EGFR, HER2, and TOP2A genes
in patients prior to treatment.
Previous studies to determine whether high EGFR copy
number was associated with EGFR overexpression have
been controversial [23-26]. Our results showed that EGFR
FISH-positive status did not correlate with EGFR overex-
pression, further studies will be required to confirm their
relationship.
Abnormalities in gene copy number or structure due to
chromosomal aneusomy or DNA aneuploidy may lead to
altered gene dosage and can directly affect the transcrip-
tional programs for some tumor-associated genes, how-
ever an increase in DNA copy number alone does not
always lead to transcriptional up-regulation[9]. Here, we
provide the first report of chromosome 7 aneusomy in
gastric carcinomas. Our results revealed that chromosome
7 polysomy was a frequent event in gastric carcinoma. We
found that chromosome 7 polysomy associated strongly
with high EGFR copy number. In contrast to a previous
report in lung cancer[11], we did not observe an associa-
tion between chromosome 7 polysomy and EGFR overex-
pression. The mechanism underlying EGFR
overexpression remains to be clarified.
Chromosome 17 harbors a number of important onco-
genes and tumor suppressor genes, including HER2,
Table 1: Relationship between EGFR copy number and EGFR protein expression
EGFR IHC EGFR FISH Total
disomy Low trisomy High trisomy Low polysomy High polysomy Amplification
Negative 25 11 0 15 7 0 58
Positive 7 13 0 13 6 3 42
Total 32 24 0 28 13 3 100
P value >0.0026*
Odds ratio 1.987
*: the association between EGFR protein expression and EGFR FISH positive (high polysomy and amplification) and negative (disomy, low trisomy, 
high trisomy and low polysomy) (P > 0.0026)
EGFR IHC Positive:IHC staining level of 2+and 3+, EGFR IHC Negative:IHC staining level of 0 and 1+.
Table 2: Relationship between chromosome 7 polysomy and EGFR copy number/EGFR protein expression
Chromosome 7 copy number EGFR FISH EGFR IHC
Negative Positive Negative Positive
Non-polysomy 74 7 48 33
P o l y s o m y 1 091 09
Total 84 16 58 42
P value <0.0001* >0.0026#
Odds ratio 8.2286 1.3091
*: association between chromosome 7 polysomy and EGFR copy number(p < 0.0001), significant after Bonferroni correction;
#: association between chromosome 7 polysomy and EGFR protein expression (p > 0.0026).
EGFR FISH Positive: EGFR high polysomy and amplification. EGFR FISH Negative:EGFR disomy, low trisomy, high trisomy, and low polysomyBMC Cancer 2008, 8:363 http://www.biomedcentral.com/1471-2407/8/363
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A: Case 36, immunohistochemistry showed HER2 2+ in gastric adenocarcinoma, B: Immunohistochemistry showed HER2 neg- ative control in gastric adenocarcinoma, C: Case 36, Immunohistochemistry showed TOP2A NI (nuclear index) 40% in gastric  adenocarcinoma, D: Immunohistochemistry showed TOP2A NI (nuclear index) less than 1% (under expression) in gastric ade- nocarcinoma, E: Case 36, FISH result showed HER2 (green signal) and TOP2A (red signal) coamplification in gastric adenocar- cinoma Figure 2
A: Case 36, immunohistochemistry showed HER2 2+ in gastric adenocarcinoma, B: Immunohistochemistry 
showed HER2 negative control in gastric adenocarcinoma, C: Case 36, Immunohistochemistry showed 
TOP2A NI (nuclear index) 40% in gastric adenocarcinoma, D: Immunohistochemistry showed TOP2A NI 
(nuclear index) less than 1% (under expression) in gastric adenocarcinoma, E: Case 36, FISH result showed 
HER2 (green signal) and TOP2A (red signal) coamplification in gastric adenocarcinoma.BMC Cancer 2008, 8:363 http://www.biomedcentral.com/1471-2407/8/363
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TOP2A, DARPP32, p53, and BRCA1[21]. In the present
study, all six HER2 3+ cases showed HER2 gene amplifica-
tion, and three HER2 2+ cases showed HER2 gene ampli-
fication. Therefore, HER2 gene amplification correlated
significantly with HER2 overexpression; this finding is
consistent with previous reports [19-21]. Chromosome
17 polysomy did not correlate with HER2 amplification
or with HER2 overexpression. Rather, our results suggest
that increased HER2 gene dosage resulting from gene
amplification is the most important determinant of HER2
overexpression, whereas any influence resulting from
polysomy for chromosome 17 alone is unlikely to play a
significant role in HER2 gene overexpression at the tran-
scriptional level; a similar finding was described previ-
ously in breast cancer [12].
The EGFR superfamily has four members: EGFR/HER1,
HER2/c-erbB-2/NEU, HER3, and HER4. The EGFR super-
family members are activated by dimerization of identical
receptors (homodimerization) or by dimerization of dif-
ferent family members (heterodimerization). No specific
ligand has been identified for HER2, which always forms
heterodimers with EGFR, HER3, or HER4; HER2-associ-
ated heterodimers showed an increased capacity for trans-
lating mitogenic signals relative to homodimers, and the
heterodimers showed a synergistic effect on cellular trans-
formation. It has been suggested that drugs designed to
target either EGFR or HER2 would be effective at least in
HER2 amplification patients; however, EGFR and HER2
do not always show high gene copy number or high pro-
tein levels at the same time. Therefore, dual inhibition
therapy designed to target EGFR and HER2 together may
prove to be an ideal regimen for EGFR- or HER2-positive
cancer patients. Very recently, small tyrosine kinase inhib-
itors that simultaneously block EGFR and HER2 have
been identified [7-9]. In the present study, we did not
identify a correlation between EGFR and HER2 protein
expression and gene copy number in gastric carcinomas:
only 7 cases showed co-expression of EGFR and HER2,
and 3 cases were simultaneously FISH-positive for EGFR
and HER2. Dual inhibitor of EGFR and HER2 may be ben-
efit to patients with gastric carcinoma.
TOP2A is among the genes reported to be co-amplified in
the HER2 amplicon at 17q12-21, and alterations in
TOP2A gene copy number are well studied because it is a
molecular target of many anti-cancer drugs termed topo II
inhibitors, including anthracyclines, epipodophyllotox-
ins, actinomycxin, and mitoxantrone[27,28]. Although
TOP2A inhibitor therapy is dependent on TOP2A expres-
sion levels, whether TOP2A gene amplification is associ-
ated with TOP2A overexpression remains
controversial[9]. Varis et al [21] reported that TOP2A gene
amplification and increased protein expression were con-
cordant, suggesting that gene amplification was largely
responsible for TOP2A overexpression. Our study showed
that TOP2A gene amplification detected by FISH did not
correlate with the TOP2A immunohistochemistry score.
This discrepancy may be due to cell cycle-dependent
expression of TOP2A, which peaks at the G2/M phase of
the cell cycle and declines to a minimum at the end of
mitosis; the immunohistochemical analysis only deter-
mined the number of proliferating cells, not the differ-
ences in the TOP2A expression levels, so the IHC score
could not be used as an indicator for TOP2A inhibitor
chemotherapy. Previously published reports suggest that
TOP2A amplification and deletion account for relative
chemosensitivity and chemoresistance, respectively, to
Table 3: Relationship between HER2 amplification and HER2 
protein expression.
HER2 IHC HER2 FISH Total
Negative Positive
Negative 89 5 94
Positive 0 6 6
Total number 89 11 100
P value <0.0001*
Odds ratio 211.546
Positive: HER2 amplification, Negative: No HER2 amplification.
*: significant after Bonferroni correction.
Table 4: Relationship between chromosome 17 copy number and HER2 amplification/HER2 protein expression
Chromosome 17 Copy number HER2 FISH HER2 IHC
Negative Positive Negative Positive
Non-polysomy 74 10 79 5
Polysomy 15 1 15 1
Total 89 11 94 6
P value >0.0026* >0.0026#
Odds ratio 0.4933 1.0533
*: Association between chromosome 17 polysomy and HER2 amplification.
#: Association between chromosome 17 polysomy and HER2 protein expression.
HER2 FISH Positive: HER2 amplification, HER2 FISH Negative: No HER2 amplification,
HER2 IHC Positive: IHC staining level of 3+, HER2 Negative: IHC staining level of 0,1+,2+BMC Cancer 2008, 8:363 http://www.biomedcentral.com/1471-2407/8/363
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TOP2A inhibitor therapy depending on the specific
genetic defect at the TOP2A locus in breast carcinoma
[29]. We did not detect TOP2A deletions in the present
study.
In our study, TOP2A amplification was not a frequent
event in gastric carcinoma; this may be the reason why
anthracycline therapies have not been effective in target-
ing gastric carcinomas. Previous studies showed that
TOP2A and HER2 were co-amplified in approximately
30–90% of breast carcinomas; the underlying molecular
mechanism for co-amplification is not known [9]. Many
reports have shown that HER2 and TOP2A co-amplifica-
tion predicted a good response to TOP2A inhibitor chem-
A: Case 6, immunohistochemistry showed EGFR 3+ in gastric adenocarcinoma, B: Case 6, immunohistochemistry showed  HER2 3+ in gastric adenocarcinoma, C: Case 6, immunohistochemistry showed TOP2A expression NI 80% in gastric adeno- carcinoma Figure 3
A: Case 6, immunohistochemistry showed EGFR 3+ in gastric adenocarcinoma, B: Case 6, immunohistochem-
istry showed HER2 3+ in gastric adenocarcinoma, C: Case 6, immunohistochemistry showed TOP2A expres-
sion NI 80% in gastric adenocarcinoma. D: Immunohistochemistry showed EGFR negative(0) control in gastric 
adenocarcinoma, E: Immunohistochemistry showed HER2 negative control in gastric adenocarcinoma, F: Immunohistochemis-
try showed TOP2A NI (nuclear index) less than 1% (under expression) in gastric adenocarcinoma G:case 6, FISH result 
showed EGFR high polysomy (red signal) in gastric adenocarcinoma, H:case 6, FISH result showed HER2 amplification (green 
signal in cluster), TOP2A FISH negative (red signal) in gastric adenocarcinoma.BMC Cancer 2008, 8:363 http://www.biomedcentral.com/1471-2407/8/363
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otherapy in breast carcinoma, and that a combined
therapy with HER2 inhibitors and TOP2A inhibitors
would be a good choice for the treatment of these cancer
patients. Our studies showed that TOP2A amplification
was associated strongly with HER2 amplification in gas-
tric carcinoma: among the ten HER2 amplification cases,
two (20%) showed TOP2A amplification, whereas one
TOP2A amplification case showed no HER2 amplification
showing that TOP2A could be amplified independent of
HER2 in gastric carcinoma. Collectively, the results of this
study are consistent with previous reports of other tumor
types [30-32].
We were unable to determine a relationship between the
alterations in EGFR, HER2, TOP2A, chromosome 7, or
chromosome 17 and the clinicopathologic characteristics
of gastric carcinoma; this is in contrast to previous reports,
TOP2A expression nuclear index in 100 cases of gastric carcinoma, NI value is from 0.5 to 90%, three cases showed TOP2A  amplification (arrows) with TOPNI values of 20%, 40%, and 50% Figure 4
TOP2A expression nuclear index in 100 cases of gastric carcinoma, NI value is from 0.5 to 90%, three cases 
showed TOP2A amplification (arrows) with TOPNI values of 20%, 40%, and 50%.
Table 5: Relationship between TOP2A gene amplification and 
TOP2A protein expression
TOP2A NI TOP2A FISH Total P value Odds ratio
Negative Positive
<5% 12 0 12 >0.0026 1.0234
≥5% 85 3 88
<10% 22 0 22 >0.0026 2.0861
≥10% 75 3 78
<25% 48 1 49 >0.0026 1.9592
≥25% 49 2 51
Positive: TOP2A amplification, Negative: No TOP2A amplification.BMC Cancer 2008, 8:363 http://www.biomedcentral.com/1471-2407/8/363
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and may be due to different sample numbers and different
populations. Further studies will need to be performed
using larger patient populations.
Conclusion
This study documented alterations in protein expression
and gene copy number for EGFR, HER2, and TOP2A in
Chinese patients with gastric carcinoma. Alterations in
HER2 and TOP2A occurred at a relatively low frequency.
HER2 gene amplification correlated significantly with
HER2 protein overexpression, whereas EGFR gene ampli-
fication and TOP2A gene amplification were not associ-
ated with corresponding increases in protein expression;
the mechanism remains to be clarified. Chromosome 7
polysomy may contribute to an increase in EGFR gene
copy number, and chromosome 17 polysomy may not be
the main reason behind HER2 gene amplification. EGFR
gene amplification did not correlate with HER2 gene
amplification, whereas TOP2A gene amplification was
associated significantly with HER2 gene amplification.
Simultaneous detection of the status of the EGFR, HER2,
and TOP2A genes may facilitate the development of effec-
tive therapeutic strategies to target gastric cancer, espe-
cially for determining those patients who may benefit
most from a combination of therapies to target EGFR and
HER2 together with a TOP2A inhibitor.
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